Filtricine Presents Research at Scientific Conference for Cancer Treatment
At the AACR-NCI-EORTC conference for molecular targets (#Targets19) at Boston, we presented our latest preclinical research on treating colon cancer and boosting anti-PD-1 immunotherapy with our “targeted nutrient deprivation” technology.
Filtricine Preclinical Results Published
Filtricine is pleased to announce that the preclinical research results of its proprietary medical food technology
Clinical Results Presented at PCF Retreat
Filtricine is pleased to announce that researchers leading a Filtricine-sponsored prostate cancer clinical study at Stanford University
We Are Excited to Announce Filtricine's Latest Round of Investment
Filtricine's Seed Round announcement, led by Boutique Venture Partners and Berkeley Catalyst Fund
Filtricine Appoints a New Chief Executive Officer
It is our great pleasure to announce that Dr. John Chant has accepted our offer as Chief Executive Officer.
Filtricine Initiates the First Clinical Study
Filtricine today announced the start of its first human clinical study among prostate cancer patients.